Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Refametinib + Regorafenib in Advanced Solid Tumors
NCT02168777Phase 1Terminated
- Sponsor
- Bayer
- Start
- Jun 2014
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of refametinib in solid tumor (3 cohorts), sponsored by Bayer. Primary endpoints: Maximum Drug Concentration in Plasma After Multiple Dose for Refametinib, Maximum Drug Concentration in Plasma After Multiple Dose for Refametinib Metabolite M-11 and 10 more. Started Jun 2014; status: terminated.
02
Drugs
refametinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02168777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02168777.